Why Does IGF-1 LR3 Bind Less to IGF-Binding Proteins?

In normal physiology, IGFBPs (there are six known types, IGFBP-1 through IGFBP-6) serve an important regulatory function: they extend IGF-1's half-life in circulation while also controlling how much of it is "free" and able to interact with cell-surface IGF-1 receptors at any given moment. More than 90% of circulating native IGF-1 is bound to IGFBPs, primarily IGFBP-3, in normal human physiology.

Because IGF-1 LR3's N-terminal modification interferes with the specific binding site IGFBPs recognize, published in-vitro binding studies report substantially reduced IGFBP affinity for the analog compared to native IGF-1. The practical research consequence is that a larger proportion of IGF-1 LR3 remains unbound and available to interact with IGF-1 receptors in a research system, which is why the analog is used in studies requiring sustained receptor engagement.

This is a structural-biology explanation, not usage guidance. REVIVE LAB UAE does not sell IGF-1 LR3, and this page contains no dosing, administration, or protocol information — it describes only the binding chemistry documented in published research.